Quarterly report pursuant to Section 13 or 15(d)

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)

v3.21.2
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 11, 2020
USD ($)
Nov. 10, 2021
USD ($)
Sep. 30, 2021
USD ($)
patent
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
patent
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Subsidiary, Sale of Stock [Line Items]                      
Number of operating segments | segment                 1    
Accumulated deficit     $ 177,782           $ 177,782   $ 150,906
Net loss     (8,984) $ (9,069) $ (8,823) $ (6,063) $ (7,215) $ (8,005) (26,876) $ (21,283)  
Cash used                 (21,900)    
Cash and cash equivalents     15,346           15,346   24,968
Accounts receivable     $ 4,261           4,261   208
Gross proceeds from sale of common stock $ 26,400               12,303 $ 28,750  
At-The-Market Equity Offering                      
Subsidiary, Sale of Stock [Line Items]                      
Gross proceeds from sale of common stock                 $ 11,900   $ 11,000
Subsequent Event | At-The-Market Equity Offering                      
Subsidiary, Sale of Stock [Line Items]                      
Gross proceeds from sale of common stock   $ 6,100                  
IP Portfolio                      
Subsidiary, Sale of Stock [Line Items]                      
Number of developed technology patents | patent     385           385    
IP Portfolio, XBAR Technology                      
Subsidiary, Sale of Stock [Line Items]                      
Number of developed technology patents | patent     235           235